Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


First point-of-care PSA test for prostate cancer detection

The FDA’s approval of the first point-of-care total PSA test for prostate cancer has the potential to improve patient care by streamlining PSA testing. However, a Clinical Laboratory Improvement Amendments waiver is needed before this test can be fully integrated into clinical care.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: A microfluidic-based immunoassay employing Sangia technology.


  1. 1.

    U.S. Food and Drug Administration. Recently-approved devices: Sangia Total PSA Test - P170037. FDA (updated 31 Jan 2019).

  2. 2.

    U.S. Food and Drug Administration. Summary of safety and effectiveness data (SSED). FDA (2019).

  3. 3.

    OPKO Diagnostics. Instructions for use. FDA (2019).

  4. 4.

    Loeb, S. et al. How active is active surveillance? Intensity of followup during active surveillance for prostate cancer in the United States. J. Urol. 196, 721–726 (2016).

    Article  Google Scholar 

  5. 5.

    Centers for Medicare & Medicaid Services. Clinical laboratory improvement amendments (CLIA). CMS (updated 24 Feb 2019).

  6. 6.

    Centers for Medicare & Medicaid Services. How to obtain a CLIA certificate of waiver. CMS (2006).

Download references

Author information



Corresponding author

Correspondence to Michael A. Gorin.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Meyer, A.R., Gorin, M.A. First point-of-care PSA test for prostate cancer detection. Nat Rev Urol 16, 331–332 (2019).

Download citation

Further reading


Quick links